Femasys Inc. (NASDAQ:FEMY – Get Rating) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 131,700 shares, a decline of 51.1% from the March 31st total of 269,200 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 206,000 shares, the short-interest ratio is presently 0.6 days.
Several institutional investors and hedge funds have recently made changes to their positions in FEMY. Millennium Management LLC bought a new position in shares of Femasys in the 2nd quarter valued at $109,000. BlackRock Inc. acquired a new stake in Femasys in the third quarter valued at $40,000. Tri Locum Partners LP increased its holdings in Femasys by 1.0% in the third quarter. Tri Locum Partners LP now owns 190,600 shares of the company’s stock valued at $1,313,000 after purchasing an additional 1,847 shares during the period. Clear Creek Financial Management LLC increased its holdings in Femasys by 190.2% in the fourth quarter. Clear Creek Financial Management LLC now owns 68,276 shares of the company’s stock valued at $266,000 after purchasing an additional 44,752 shares during the period. Finally, Oppenheimer & Co. Inc. acquired a new stake in Femasys in the fourth quarter valued at $514,000. Institutional investors own 6.27% of the company’s stock.
Several equities research analysts recently issued reports on FEMY shares. Chardan Capital cut their price target on Femasys from $25.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, March 25th. Zacks Investment Research upgraded Femasys from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Friday, December 31st. Finally, HC Wainwright assumed coverage on Femasys in a research note on Thursday, March 24th. They set a “buy” rating and a $8.00 target price for the company.
Femasys (NASDAQ:FEMY – Get Rating) last announced its quarterly earnings results on Thursday, March 24th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $0.25 million during the quarter. Sell-side analysts predict that Femasys will post -0.93 earnings per share for the current fiscal year.
Femasys Company Profile (Get Rating)
Femasys Inc, a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.
- Get a free copy of the StockNews.com research report on Femasys (FEMY)
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
- Iridium Communications Stock is Ready to Return to Orbit
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.